Sweden · Delayed Price · Currency is SEK Novakand Pharma AB Statistics
Total Valuation
STO:NOVKAN has a market cap or net worth of SEK 15.39 million. The enterprise value is -6.88 million.
| Market Cap | 15.39M |
| Enterprise Value | -6.88M |
Important Dates
The next estimated earnings date is Friday, February 20, 2026.
| Earnings Date | Feb 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:NOVKAN has 121.19 million shares outstanding. The number of shares has increased by 17.04% in one year.
| Current Share Class | 121.19M |
| Shares Outstanding | 121.19M |
| Shares Change (YoY) | +17.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.93% |
| Owned by Institutions (%) | 14.05% |
| Float | 111.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.13 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.34
| Current Ratio | 7.34 |
| Quick Ratio | 7.24 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -112.87% and return on invested capital (ROIC) is -46.89%.
| Return on Equity (ROE) | -112.87% |
| Return on Assets (ROA) | -42.81% |
| Return on Invested Capital (ROIC) | -46.89% |
| Return on Capital Employed (ROCE) | -172.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -10.38M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.47% in the last 52 weeks. The beta is 1.10, so STO:NOVKAN's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -86.47% |
| 50-Day Moving Average | 0.17 |
| 200-Day Moving Average | 0.80 |
| Relative Strength Index (RSI) | 41.31 |
| Average Volume (20 Days) | 632,282 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -34.50M |
| Pretax Income | -51.90M |
| Net Income | -51.90M |
| EBITDA | n/a |
| EBIT | -34.50M |
| Earnings Per Share (EPS) | -0.43 |
Balance Sheet
The company has 22.27 million in cash and n/a in debt, with a net cash position of 22.27 million or 0.18 per share.
| Cash & Cash Equivalents | 22.27M |
| Total Debt | n/a |
| Net Cash | 22.27M |
| Net Cash Per Share | 0.18 |
| Equity (Book Value) | 20.03M |
| Book Value Per Share | 0.17 |
| Working Capital | 20.03M |
Cash Flow
| Operating Cash Flow | -35.66M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
STO:NOVKAN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.04% |
| Shareholder Yield | -17.04% |
| Earnings Yield | -337.22% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 24, 2021. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 24, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |